Cross-Sector entity
Donald Trump is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The clearest coverage concentration is pharma: 1 of 2 stories, with the rest divided among 1 other category. Sudarshan Jain appears in 2 tracked Cross-Sector stories from August 1, 2026.
2 verified stories tracked
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Donald Trump is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The clearest coverage concentration is pharma: 1 of 2 stories, with the rest divided among 1 other category. Sudarshan Jain appears in 2 tracked Cross-Sector stories from August 1, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Sudarshan Jain. Shared-story counts are live from our verified record — not editorial picks.
A proposed US tariff of up to 200% on generic drug imports threatens to sever the supply of affordable medicines from India, potentially causing shortages and billions in added costs for hospitals and patients. Industry experts warn that manufacturers cannot absorb the tariffs and may exit the US market, directly undermining efforts to control healthcare spending.
The proposed US tariff on generic drugs—jumping to 200%—poses an existential threat to Indian pharmaceutical companies that have long dominated the American market. With margins razor-thin and a 4-5 year timeline needed to onshore production, industry leaders call the plan 'completely out of scope,' potentially forcing a major restructuring of global generic supply chains.
Source: heraldglobe.com · milwaukeesun.com
